全体要約
特発性肺線維症は、数年にわたって進行する稀な慢性疾患で、肺に瘢痕組織が形成され、呼吸困難を引き起こします。2023年の特発性肺線維症の治療市場は、数百万米ドルと推定され、2030年には同様の規模に調整される見込みです。2022年の世界の製薬市場は1475億米ドルで、今後6年間で5%の成長が予測されています。
特発性肺線維症の治療市場は、ピルフェニドンやニンテダニブなどの薬剤が含まれ、地域別や用途別に分析されます。市場の競争状況や主要企業のシェア、売上高の推移も詳細に示され、2019年から2030年までのデータが提供されます。
関連する質問
Boehringer Ingelheim, Merck and Co., Inc., ArkBio, Zelgen, Blade Therapeutics, Regend Therapeutics (Cayman) Ltd., Insilico Medicine, Vicore Pharma, Heilongjiang Zbd Pharmaceutical, Indaco, InterMune, Inc., Bristol Myers Squibb, SHIONOGI & CO., Ltd.
医療ニーズの高まり, 技術革新の進展, 慢性疾患の有病率の上昇
概要
特発性肺線維症治療の世界市場は、2023年にXX米ドルの価値があると推定され、2030年までにXX米ドルに再調整されると予測されており、2024年から2030年にかけてのCAGRはXX%です。
2022年の世界の医薬品市場は1475億米ドルであり、今後6年間で年平均成長率（CAGR）が5%で成長すると予測されています。医薬品市場には化学薬品と生物製剤が含まれています。生物製剤の市場は2022年に381億米ドルに達すると期待されています。それに対して、化学薬品市場は2018年の1005億米ドルから2022年には1094億米ドルに増加すると推定されています。医薬品市場には、医療に対する需要の増加、技術の進歩、慢性疾患の蔓延の増加、医薬品製造セグメントの発展のための民間及び政府機関からの資金提供の増加、そして薬剤の研究開発活動の増加といった要因が含まれます。しかし、業界は厳しい規制、高い研究開発コスト、特許の失効といった課題にも直面しています。企業は、競争力を維持し、必要な患者に製品を届けるために、これらの課題に継続的に革新し適応する必要があります。さらに、COVID-19パンデミックはワクチン開発とサプライチェーン管理の重要性を際立たせ、医薬品企業が新たな公衆衛生ニーズに迅速かつ柔軟に対応する必要性をさらに強調しています。
報告の範囲
この報告書は、特発性肺線維症治療の世界市場について、総売上高、主要企業の市場シェアとランキング、地域別および国別、タイプ別、アプリケーション別の特発性肺線維症治療の分析を提供することを目的としています。
特発性肺線維症治療市場の規模、推定、予測は、2023年を基準年とし、2019年から2030年までの期間の履歴データと予測データを考慮して、売上高（百万ドル）で提供されています。定量的および定性的な分析を用いて、読者がビジネス/成長戦略を開発し、市場の競争状況を評価し、現在の市場における自分の立場を分析し、特発性肺線維症治療に関する情報に基づいたビジネス判断を行う手助けをします。
市場セグメンテーション
会社別
ボーリングエンゲルハイム
メルク社
アークバイオ
ゼルゲン
ブレード・セラピューティクス
レジェンドセラピューティクス（ケイマン）有限公司
インシリコ・メディスン
ビコールファーマ
ハイロング江Zbd製薬
インダコ
インタームーン株式会社
ブリストール・マイヤーズ スクイブ
塩野義製薬株式会社
タイプ別セグメント：
ピルフェニドン
ニンテダニブ
他の
アプリケーションによるセグメント
病院
大学院
その他
地域別
北アメリカ
アメリカ合衆国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東およびアフリカ
トルコ
サウジアラビア
UAE（アラブ首長国連邦）
章の概要
第1章：レポートの範囲、世界の総市場規模を紹介します。この章では、市場の動向、市場の最新の発展、市場の推進要因と制約要因、業界の製造業者が直面する課題とリスク、業界に関連する政策の分析も提供します。
第2章：特発性肺線維症治療製造業者の競争環境、収益市場シェア、最新の開発計画、合併および買収情報などの詳細分析です。
第3章：タイプ別のさまざまな市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのを助けます。
第4章：アプリケーション別のさまざまな market segments の分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場でブルーオーシャン市場を見つける手助けをします。
第5章：地域別特発性肺線維症治療の収益。各地域の市場規模と発展可能性に関する定量的分析を提供し、各国の市場発展、将来の発展見通し、市場スペース、及び市場規模を紹介します。
第6章：特発性間質性肺炎治療の国別収益。国/地域ごとにタイプおよびアプリケーション別のシグマデータを提供します。
第7章：主要プレーヤーのプロファイルを提供し、市場の主要企業の基本状況を詳細に紹介します。これには、製品収益、総利益率、製品導入、最近の開発などが含まれます。
第8章: 産業チェーンの分析、業界の上流と下流を含みます。
第9章: 結論。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 市場概要
1.1 特発性肺線維症の治療 : プロダクトのイントロダクション
1.2 グローバルの市場規模、市場予測
1.3 特発性肺線維症の治療市場トレンドと成長ドライバー
1.3.1 特発性肺線維症の治療業界トレンド
1.3.2 特発性肺線維症の治療市場のドライバーと事業機会
1.3.3 特発性肺線維症の治療市場の課題
1.3.4 特発性肺線維症の治療市場の抑制要因
1.4 前提条件と限界
1.5 調査の目的
1.6 対象年
2 競合分析、企業別
2.1 グローバルの特発性肺線維症の治療、プレイヤー収益ランキング（2023年）
2.2 グローバルにおける特発性肺線維症の治療市場の収益規模、企業別（2019年～2024年）
2.3 特発性肺線維症の治療の主要企業、製造・販売拠点およびヘッドクオーター
2.4 特発性肺線維症の治療の主要企業、製品展開
2.5 特発性肺線維症の治療の主要企業、量産開始時期
2.6 特発性肺線維症の治療市場の競争状況分析
2.6.1 特発性肺線維症の治療市場集中度比率（2019年～2024年）
2.6.2 グローバルの特発性肺線維症の治療、上位企業5～10社の収益（2023年）
2.6.3 グローバルの特発性肺線維症の治療、Tier別上位企業（Tier 1、Tier 2、Tier 3）、2023年の収益ベース
2.7 M&A、拡大
3 セグメンテーション、タイプ別
3.1 イントロダクション、タイプ別
3.1.1 ピルフェニドン
3.1.2 ニンテダニブ
3.1.3 その他
3.2 グローバルの特発性肺線維症の治療の売上規模、金額ベース、タイプ別
3.2.1 グローバルの特発性肺線維症の治療の売上規模、金額ベース、タイプ別（2019年、2023年、2030年）
3.2.2 グローバルの特発性肺線維症の治療の売上規模、金額ベース、タイプ別（2019年～2030年）
3.2.3 グローバルの特発性肺線維症の治療の売上規模、金額ベース、タイプ別（%）（2019年～2030年）
4 セグメンテーション、用途別
4.1 イントロダクション、用途別
4.1.1 病院
4.1.2 大学院
4.1.3 その他
4.2 グローバルの特発性肺線維症の治療の売上規模、金額ベース、用途別
4.2.1 グローバルの特発性肺線維症の治療の売上規模、金額ベース、用途別（2019年、2023年、2030年）
4.2.2 グローバルの特発性肺線維症の治療の売上規模、金額ベース、用途別（2019年～2030年）
4.2.3 グローバルの特発性肺線維症の治療の売上規模、金額ベース、用途別（%）（2019年～2030年）
5 セグメンテーション、地域別
5.1 グローバルの特発性肺線維症の治療の売上規模、金額ベース、地域別
5.2 北米
5.2.1 北米の特発性肺線維症の治療売上規模、金額ベース、2019年～2030年
5.2.2 北米の特発性肺線維症の治療の売上規模、金額ベース、国別（%）、2023年、2030年
5.3 ヨーロッパ
5.3.1 ヨーロッパの特発性肺線維症の治療売上規模、金額ベース、2019年～2030年
5.3.2 ヨーロッパの特発性肺線維症の治療の売上規模、金額ベース、国別（%）、2023年、2030年
5.4 アジア太平洋
5.4.1 アジア太平洋の特発性肺線維症の治療売上規模、金額ベース、2019年～2030年
5.4.2 アジア太平洋の特発性肺線維症の治療の売上規模、金額ベース、国別（%）、2023年、2030年
5.5 南米
5.5.1 南米の特発性肺線維症の治療売上規模、金額ベース、2019年～2030年
5.5.2 南米の特発性肺線維症の治療の売上規模、金額ベース、国別（%）、2023年、2030年
5.6 中東・アフリカ
5.6.1 中東・アフリカの特発性肺線維症の治療売上規模、金額ベース、2019年～2030年
5.6.2 中東・アフリカの特発性肺線維症の治療の売上規模、金額ベース、国別（%）、2023年、2030年
6 主要国・地域によるセグメンテーション
6.1 主要国・地域の特発性肺線維症の治療の売上成長トレンド、金額ベース（2019年、2023年、2030年）
6.2 主要国・地域の特発性肺線維症の治療の売上、金額ベース
6.3 米国
6.4 ヨーロッパ
6.5 中国
6.6 日本
6.7 韓国
6.8 東南アジア
6.9 インド
7 企業プロファイル
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim : プロファイル
7.1.2 Boehringer Ingelheim : 主な事業
7.1.3 Boehringer Ingelheim : 特発性肺線維症の治療の製品、サービス、ソリューション
7.1.4 Boehringer Ingelheim : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.1.5 Boehringer Ingelheim：近況
7.2 Merck and Co\., Inc
7.3 ArkBio
7.3.1 ArkBio : プロファイル
7.3.2 ArkBio : 主な事業
7.3.3 ArkBio : 特発性肺線維症の治療の製品、サービス、ソリューション
7.3.4 ArkBio : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.3.5 Zelgen：近況
7.4 Zelgen
7.4.1 Zelgen : プロファイル
7.4.2 Zelgen : 主な事業
7.4.3 Zelgen : 特発性肺線維症の治療の製品、サービス、ソリューション
7.4.4 Zelgen : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.4.5 Zelgen：近況
7.5 Blade Therapeutics
7.5.1 Blade Therapeutics : プロファイル
7.5.2 Blade Therapeutics : 主な事業
7.5.3 Blade Therapeutics : 特発性肺線維症の治療の製品、サービス、ソリューション
7.5.4 Blade Therapeutics : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.5.5 Blade Therapeutics：近況
7.6 Regend Therapeutics \(Cayman\) Ltd
7.7 Insilico Medicine
7.7.1 Insilico Medicine : プロファイル
7.7.2 Insilico Medicine : 主な事業
7.7.3 Insilico Medicine : 特発性肺線維症の治療の製品、サービス、ソリューション
7.7.4 Insilico Medicine : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.7.5 Insilico Medicine：近況
7.8 Vicore Pharma
7.8.1 Vicore Pharma : プロファイル
7.8.2 Vicore Pharma : 主な事業
7.8.3 Vicore Pharma : 特発性肺線維症の治療の製品、サービス、ソリューション
7.8.4 Vicore Pharma : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.8.5 Vicore Pharma：近況
7.9 Heilongjiang Zbd Pharmaceutical
7.9.1 Heilongjiang Zbd Pharmaceutical : プロファイル
7.9.2 Heilongjiang Zbd Pharmaceutical : 主な事業
7.9.3 Heilongjiang Zbd Pharmaceutical : 特発性肺線維症の治療の製品、サービス、ソリューション
7.9.4 Heilongjiang Zbd Pharmaceutical : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.9.5 Heilongjiang Zbd Pharmaceutical：近況
7.10 Indaco
7.10.1 Indaco : プロファイル
7.10.2 Indaco : 主な事業
7.10.3 Indaco : 特発性肺線維症の治療の製品、サービス、ソリューション
7.10.4 Indaco : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.10.5 Indaco：近況
7.11 InterMune, Inc
7.12 Bristol Myers Squibb
7.12.1 Bristol Myers Squibb : プロファイル
7.12.2 Bristol Myers Squibb : 主な事業
7.12.3 Bristol Myers Squibb : 特発性肺線維症の治療の製品、サービス、ソリューション
7.12.4 Bristol Myers Squibb : 特発性肺線維症の治療の収益（百万米ドル）（2019年～2024年）
7.12.5 Bristol Myers Squibb：近況
7.13 SHIONOGI & CO\., Ltd
8 業界チェーン分析
8.1 特発性肺線維症の治療業界バリューチェーン
8.2 特発性肺線維症の治療市場の上流分析
8.2.1 主要原材料
8.2.2 原材料と主要サプライヤー
8.2.3 製造コスト構造
8.3 中流分析
8.4 下流分析（顧客についての分析）
8.5 営業販売モデル、販売チャネル
8.5.1 特発性肺線維症の治療 営業販売モデル
8.5.2 販売チャネル
8.5.3 特発性肺線維症の治療の流通業者
9 調査の結果・結論
10 付録
10.1 調査手法
10.1.1 調査手法 / 調査アプローチ
10.1.2 データソース
10.2 執筆者の詳細
10.3 免責事項
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The global market for Idiopathic Pulmonary Fibrosis Disease Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis Disease Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Idiopathic Pulmonary Fibrosis Disease Treatment by region & country, by Type, and by Application.
The Idiopathic Pulmonary Fibrosis Disease Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Pulmonary Fibrosis Disease Treatment.
Market Segmentation
By Company
Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
Segment by Type:
Pirfenidone
Nintedanib
Other
Segment by Application
Hospital
Graduate School
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Idiopathic Pulmonary Fibrosis Disease Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Idiopathic Pulmonary Fibrosis Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Idiopathic Pulmonary Fibrosis Disease Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Idiopathic Pulmonary Fibrosis Disease Treatment Product Introduction
1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast
1.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Trends & Drivers
1.3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends
1.3.2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Drivers & Opportunity
1.3.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Challenges
1.3.4 Idiopathic Pulmonary Fibrosis Disease Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Players Revenue Ranking (2023)
2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Company (2019-2024)
2.3 Key Companies Idiopathic Pulmonary Fibrosis Disease Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Idiopathic Pulmonary Fibrosis Disease Treatment
2.6 Idiopathic Pulmonary Fibrosis Disease Treatment Market Competitive Analysis
2.6.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Pirfenidone
3.1.2 Nintedanib
3.1.3 Other
3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type
3.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Graduate School
4.1.3 Others
4.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application
4.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region
5.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2019-2024)
5.1.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2025-2030)
5.1.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.2.2 North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.3.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.5.2 South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value
6.3 United States
6.3.1 United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.3.2 United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.4.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.5.2 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.6.2 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.7.2 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.9.2 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim Profile
7.1.2 Boehringer Ingelheim Main Business
7.1.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.1.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Boehringer Ingelheim Recent Developments
7.2 Merck and Co., Inc.
7.2.1 Merck and Co., Inc. Profile
7.2.2 Merck and Co., Inc. Main Business
7.2.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.2.4 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Merck and Co., Inc. Recent Developments
7.3 ArkBio
7.3.1 ArkBio Profile
7.3.2 ArkBio Main Business
7.3.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.3.4 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Zelgen Recent Developments
7.4 Zelgen
7.4.1 Zelgen Profile
7.4.2 Zelgen Main Business
7.4.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.4.4 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Zelgen Recent Developments
7.5 Blade Therapeutics
7.5.1 Blade Therapeutics Profile
7.5.2 Blade Therapeutics Main Business
7.5.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.5.4 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Blade Therapeutics Recent Developments
7.6 Regend Therapeutics (Cayman) Ltd.
7.6.1 Regend Therapeutics (Cayman) Ltd. Profile
7.6.2 Regend Therapeutics (Cayman) Ltd. Main Business
7.6.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.6.4 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Regend Therapeutics (Cayman) Ltd. Recent Developments
7.7 Insilico Medicine
7.7.1 Insilico Medicine Profile
7.7.2 Insilico Medicine Main Business
7.7.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.7.4 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Insilico Medicine Recent Developments
7.8 Vicore Pharma
7.8.1 Vicore Pharma Profile
7.8.2 Vicore Pharma Main Business
7.8.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.8.4 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Vicore Pharma Recent Developments
7.9 Heilongjiang Zbd Pharmaceutical
7.9.1 Heilongjiang Zbd Pharmaceutical Profile
7.9.2 Heilongjiang Zbd Pharmaceutical Main Business
7.9.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.9.4 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Heilongjiang Zbd Pharmaceutical Recent Developments
7.10 Indaco
7.10.1 Indaco Profile
7.10.2 Indaco Main Business
7.10.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.10.4 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Indaco Recent Developments
7.11 InterMune, Inc.
7.11.1 InterMune, Inc. Profile
7.11.2 InterMune, Inc. Main Business
7.11.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.11.4 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 InterMune, Inc. Recent Developments
7.12 Bristol Myers Squibb
7.12.1 Bristol Myers Squibb Profile
7.12.2 Bristol Myers Squibb Main Business
7.12.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.12.4 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Bristol Myers Squibb Recent Developments
7.13 SHIONOGI & CO., Ltd.
7.13.1 SHIONOGI & CO., Ltd. Profile
7.13.2 SHIONOGI & CO., Ltd. Main Business
7.13.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.13.4 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 SHIONOGI & CO., Ltd. Recent Developments
8 Industry Chain Analysis
8.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industrial Chain
8.2 Idiopathic Pulmonary Fibrosis Disease Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Idiopathic Pulmonary Fibrosis Disease Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Idiopathic Pulmonary Fibrosis Disease Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables Table 1. Idiopathic Pulmonary Fibrosis Disease Treatment Market Trends Table 2. Idiopathic Pulmonary Fibrosis Disease Treatment Market Drivers & Opportunity Table 3. Idiopathic Pulmonary Fibrosis Disease Treatment Market Challenges Table 4. Idiopathic Pulmonary Fibrosis Disease Treatment Market Restraints Table 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Company (2019-2024) & (US$ Million) Table 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Company (2019-2024) Table 7. Key Companies Idiopathic Pulmonary Fibrosis Disease Treatment Manufacturing Base Distribution and Headquarters Table 8. Key Companies Idiopathic Pulmonary Fibrosis Disease Treatment Product Type Table 9. Key Companies Time to Begin Mass Production of Idiopathic Pulmonary Fibrosis Disease Treatment Table 10. Global Idiopathic Pulmonary Fibrosis Disease Treatment Companies Market Concentration Ratio (CR5 and HHI) Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment as of 2023) Table 12. Mergers & Acquisitions, Expansion Plans Table 13. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million) Table 14. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2019-2024) & (US$ Million) Table 15. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2025-2030) & (US$ Million) Table 16. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Market Share in Value by Type (2019-2024) & (%) Table 17. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Market Share in Value by Type (2025-2030) & (%) Table 18. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million) Table 19. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2019-2024) & (US$ Million) Table 20. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2025-2030) & (US$ Million) Table 21. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Market Share in Value by Application (2019-2024) & (%) Table 22. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Market Share in Value by Application (2025-2030) & (%) Table 23. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 24. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2019-2024) & (US$ Million) Table 25. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2025-2030) & (US$ Million) Table 26. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2019-2024) & (%) Table 27. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2025-2030) & (%) Table 28. Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030 Table 29. Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2024) & (US$ Million) Table 30. Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2025-2030) & (US$ Million) Table 31. Boehringer Ingelheim Basic Information List Table 32. Boehringer Ingelheim Description and Business Overview Table 33. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 34. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Boehringer Ingelheim (2019-2024) Table 35. Boehringer Ingelheim Recent Developments Table 36. Merck and Co., Inc. Basic Information List Table 37. Merck and Co., Inc. Description and Business Overview Table 38. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 39. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Merck and Co., Inc. (2019-2024) Table 40. Merck and Co., Inc. Recent Developments Table 41. ArkBio Basic Information List Table 42. ArkBio Description and Business Overview Table 43. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 44. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of ArkBio (2019-2024) Table 45. ArkBio Recent Developments Table 46. Zelgen Basic Information List Table 47. Zelgen Description and Business Overview Table 48. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 49. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Zelgen (2019-2024) Table 50. Zelgen Recent Developments Table 51. Blade Therapeutics Basic Information List Table 52. Blade Therapeutics Description and Business Overview Table 53. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 54. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Blade Therapeutics (2019-2024) Table 55. Blade Therapeutics Recent Developments Table 56. Regend Therapeutics (Cayman) Ltd. Basic Information List Table 57. Regend Therapeutics (Cayman) Ltd. Description and Business Overview Table 58. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 59. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Regend Therapeutics (Cayman) Ltd. (2019-2024) Table 60. Regend Therapeutics (Cayman) Ltd. Recent Developments Table 61. Insilico Medicine Basic Information List Table 62. Insilico Medicine Description and Business Overview Table 63. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 64. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Insilico Medicine (2019-2024) Table 65. Insilico Medicine Recent Developments Table 66. Vicore Pharma Basic Information List Table 67. Vicore Pharma Description and Business Overview Table 68. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 69. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Vicore Pharma (2019-2024) Table 70. Vicore Pharma Recent Developments Table 71. Heilongjiang Zbd Pharmaceutical Basic Information List Table 72. Heilongjiang Zbd Pharmaceutical Description and Business Overview Table 73. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 74. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Heilongjiang Zbd Pharmaceutical (2019-2024) Table 75. Heilongjiang Zbd Pharmaceutical Recent Developments Table 76. Indaco Basic Information List Table 77. Indaco Description and Business Overview Table 78. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 79. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Indaco (2019-2024) Table 80. Indaco Recent Developments Table 81. InterMune, Inc. Basic Information List Table 82. InterMune, Inc. Description and Business Overview Table 83. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 84. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of InterMune, Inc. (2019-2024) Table 85. InterMune, Inc. Recent Developments Table 86. Bristol Myers Squibb Basic Information List Table 87. Bristol Myers Squibb Description and Business Overview Table 88. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 89. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of Bristol Myers Squibb (2019-2024) Table 90. Bristol Myers Squibb Recent Developments Table 91. SHIONOGI & CO., Ltd. Basic Information List Table 92. SHIONOGI & CO., Ltd. Description and Business Overview Table 93. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions Table 94. Revenue (US$ Million) in Idiopathic Pulmonary Fibrosis Disease Treatment Business of SHIONOGI & CO., Ltd. (2019-2024) Table 95. SHIONOGI & CO., Ltd. Recent Developments Table 96. Key Raw Materials Lists Table 97. Raw Materials Key Suppliers Lists Table 98. Idiopathic Pulmonary Fibrosis Disease Treatment Downstream Customers Table 99. Idiopathic Pulmonary Fibrosis Disease Treatment Distributors List Table 100. Research Programs/Design for This Report Table 101. Key Data Information from Secondary Sources Table 102. Key Data Information from Primary Sources Table 103. Business Unit and Senior & Team Lead Analysts List of Figures Figure 1. Idiopathic Pulmonary Fibrosis Disease Treatment Product Picture Figure 2. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2019-2030) & (US$ Million) Figure 4. Idiopathic Pulmonary Fibrosis Disease Treatment Report Years Considered Figure 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Players Revenue Ranking (2023) & (US$ Million) Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue in 2023 Figure 7. Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 8. Pirfenidone Picture Figure 9. Nintedanib Picture Figure 10. Other Picture Figure 11. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million) Figure 12. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Market Share by Type, 2023 & 2030 Figure 13. Product Picture of Hospital Figure 14. Product Picture of Graduate School Figure 15. Product Picture of Others Figure 16. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million) Figure 17. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Market Share by Application, 2023 & 2030 Figure 18. North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2019-2030) & (US$ Million) Figure 19. North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030 Figure 20. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2019-2030) & (US$ Million) Figure 21. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030 Figure 22. Asia Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2019-2030) & (US$ Million) Figure 23. Asia Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030 Figure 24. South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2019-2030) & (US$ Million) Figure 25. South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030 Figure 26. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2019-2030) & (US$ Million) Figure 27. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030 Figure 28. Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (%), (2019-2030) Figure 29. United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 30. United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 31. United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 32. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 33. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 34. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 35. China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 36. China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 37. China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 38. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 39. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 40. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 41. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 42. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 43. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 44. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 45. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 46. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 47. India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, (2019-2030) & (US$ Million) Figure 48. India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030 Figure 49. India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (%), 2023 VS 2030 Figure 50. Idiopathic Pulmonary Fibrosis Disease Treatment Industrial Chain Figure 51. Idiopathic Pulmonary Fibrosis Disease Treatment Manufacturing Cost Structure Figure 52. Channels of Distribution (Direct Sales, and Distribution) Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation
